These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1027 related items for PubMed ID: 8883281

  • 1. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA.
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [Abstract] [Full Text] [Related]

  • 2. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
    Sartorio A, Cattaneo M, Bucciarelli P, Bottasso B, Porretti S, Epaminonda P, Faglia G, Arosio M.
    Exp Clin Endocrinol Diabetes; 2000 Sep; 108(7):486-92. PubMed ID: 11083070
    [Abstract] [Full Text] [Related]

  • 3. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 5. Effect of growth hormone on fibrinolytic system in rat.
    Bubber P, Singh KP, Arora S, Bansal DD.
    Indian J Exp Biol; 1998 May; 36(5):514-6. PubMed ID: 9717468
    [Abstract] [Full Text] [Related]

  • 6. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A, Ruusuvaara L.
    Thromb Haemost; 1988 Dec 22; 60(3):361-4. PubMed ID: 3149043
    [Abstract] [Full Text] [Related]

  • 7. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.
    Wien Klin Wochenschr; 2001 Feb 15; 113(3-4):113-8. PubMed ID: 11253736
    [Abstract] [Full Text] [Related]

  • 8. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K, Alhenc-Gelas M, Pornin M, Bydlowski S, Seigneur E, Benetos A, Kierzin JM, Scarabin PY, Ducimetiere P, Aiach M, Guize L, Consoli SM.
    Am J Cardiol; 2006 May 01; 97(9):1287-91. PubMed ID: 16635597
    [Abstract] [Full Text] [Related]

  • 9. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG, Bots ML, Haverkate F, Meyer P, Hofman A, Grobbee DE, Kluft C.
    Thromb Haemost; 1999 Feb 01; 81(2):275-80. PubMed ID: 10064006
    [Abstract] [Full Text] [Related]

  • 10. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL, Boquete HR, Stalldecker G, Giaccio AV, Sobrado PG.
    Growth Horm IGF Res; 2008 Aug 01; 18(4):318-24. PubMed ID: 18289903
    [Abstract] [Full Text] [Related]

  • 11. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
    Farhan S, Winzer C, Tura A, Quehenberger P, Bieglmaier C, Wagner OF, Huber K, Waldhäusl W, Pacini G, Kautzky-Willer A.
    Eur J Clin Invest; 2006 May 01; 36(5):345-52. PubMed ID: 16634839
    [Abstract] [Full Text] [Related]

  • 12. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
    Rosenfalck AM, Fisker S, Hilsted J, Dinesen B, Vølund A, Jørgensen JO, Christiansen JS, Madsbad S.
    Growth Horm IGF Res; 1999 Apr 01; 9(2):96-105. PubMed ID: 10373342
    [Abstract] [Full Text] [Related]

  • 13. Serum homocysteine concentrations in children with growth hormone (GH) deficiency before and after 12 months GH replacement.
    Esposito V, Di Biase S, Lettiero T, Labella D, Simeone R, Salerno M.
    Clin Endocrinol (Oxf); 2004 Nov 01; 61(5):607-11. PubMed ID: 15521964
    [Abstract] [Full Text] [Related]

  • 14. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
    Primrose JN, Davies JA, Prentice CR, Hughes R, Johnston D.
    Thromb Haemost; 1992 Oct 05; 68(4):396-9. PubMed ID: 1448769
    [Abstract] [Full Text] [Related]

  • 15. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, Fryklund L, Murgatroyd PR, Dunger DB.
    Clin Endocrinol (Oxf); 2005 Oct 05; 63(4):428-36. PubMed ID: 16181235
    [Abstract] [Full Text] [Related]

  • 16. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK, Cooper JA, Howarth DJ, Meade TW, Miller GJ.
    Thromb Haemost; 1998 Mar 05; 79(3):587-90. PubMed ID: 9531046
    [Abstract] [Full Text] [Related]

  • 17. A randomised, controlled study of the effects of aerobic exercise and dietary fish on coagulation and fibrinolytic factors in type 2 diabetics.
    Dunstan DW, Mori TA, Puddey IB, Beilin LJ, Burke V, Morton AR, Stanton KG.
    Thromb Haemost; 1999 Mar 05; 81(3):367-72. PubMed ID: 10102462
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y, Okumura KI, Yoshida N, Tayama K, Takemura Y, Inukai T.
    Exp Clin Endocrinol Diabetes; 2004 Apr 05; 112(4):175-80. PubMed ID: 15127320
    [Abstract] [Full Text] [Related]

  • 19. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B, Guzic-Salobir B, Sebestjen M, Keber I.
    Menopause; 2006 Apr 05; 13(4):643-50. PubMed ID: 16837886
    [Abstract] [Full Text] [Related]

  • 20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D, Kremplewska-Nalezyta E, Gadomska G, Zastawna E, Michalski A, Drewniak W.
    Med Sci Monit; 2000 Apr 05; 6(4):684-91. PubMed ID: 11208392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.